TimeScale Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

TimeScale Financial’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$2.41K	–	645
2023 Q1	$2.41K	Hold	100	–	–	﹤0.01%	477
2022 Q4	$450	Hold	100	–	–	﹤0.01%	540
2022 Q3	$0	Hold	100	–	–	﹤0.01%	595
2022 Q2	$0	Hold	100	–	–	﹤0.01%	577
2022 Q1	$1K	Hold	100	–	–	﹤0.01%	517
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	511
2021 Q3	$1K	Hold	100	–	–	﹤0.01%	498
2021 Q2	$1K	Hold	100	–	–	﹤0.01%	500
2021 Q1	$1K	Hold	100	–	–	﹤0.01%	501
2020 Q4	$2K	Hold	100	–	–	﹤0.01%	389
2020 Q3	$1K	Buy	+100	New	+$1.26K	﹤0.01%	445

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

TimeScale Financial's PRVB Position: Q2 2023 in Review

TimeScale Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 100 shares — an estimated $2.41K sold.

TimeScale Financial first reported a position in PRVB in Q3 2020 and held it in 11 quarters. The position peaked at $2.41K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

TimeScale Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
TimeScale Financial sold 100 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.41K.
TimeScale Financial first reported a position in Provention Bio, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
TimeScale Financial's Provention Bio, Inc. Common Stock position peaked at $2.41K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.